JEFFREY J. MOLLDREM, M.D.
Osteopathic Medicine at Holcombe Blvd, Houston, TX
License number
Texas K8353
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about JEFFREY J. MOLLDREM at radaris.comName
Address
Phone
14215 Ridgewood Lake Ct, Houston, TX 77062
Houston, TX
14215 Ridgewood Lake, Pasadena, TX 77062
14215 Ridgewood Lake Ct, Houston, TX 77062
Organization information
See more information about JEFFREY J. MOLLDREM at bizstanding.comUniv-Texas MD Anderson Cancer - Jeffrey J Molldrem MD
1515 Holcombe Blvd UNIT 207, Houston, TX 77030
Categories:
Hematology Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Phone:
(713) 792-6161 (Phone)
Professional information
Dr. Jeffrey J Molldrem - MD (Doctor of Medicine)
Hospitals:
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
MD ANDERSON CANCER CENTER
1515 Holcombe Blvd, Houston 77030
MD Anderson Cancer Center
1515 Holcombe Blvd SUITE 207, Houston 77030
Montefiore Medical Center
111 East 210Th St, Bronx 10467
Saint Joseph's Medical Center
127 South Broadway, Yonkers 10701
Education:
Medical Schools
University of Mn Med Sch
Graduated: 1990
University of Mn Med Sch
Graduated: 1990
Jeffrey J Molldrem, Houston TX
Specialties:
Hematologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Education:
Doctor of Medicine
T-Cell Receptors For Use In Diagnosis And Therapy Of Cancers And Autoimmune Disease
US Patent:
2008006, Mar 13, 2008
Filed:
Jan 12, 2007
Appl. No.:
11/622723
Inventors:
Jeffrey Molldrem - Houston TX, US
International Classification:
A61K 38/00, C07H 21/04, C07K 16/00, C12N 15/00, C12Q 1/20
US Classification:
514012000, 435029000, 435320100, 530350000, 536023500
Abstract:
The specification describes the sequences for two T-cell receptors—one having a high affinity and one having low affinity for the HLA-A2-restricted peptide PR1. Use of the T-cell receptors and variants thereof in the diagnosis and treatment of cancer and immune-related diseases are also provided.
Monoclonal Antibodies For Use In Diagnosis And Therapy Of Cancers And Autoimmune Disease
US Patent:
2011029, Dec 1, 2011
Filed:
Dec 7, 2009
Appl. No.:
13/132844
Inventors:
Jeffrey J. Molldrem - Houston TX, US
Anna Sergeeva - Houston TX, US
Anna Sergeeva - Houston TX, US
International Classification:
A61K 39/395, C07K 19/00, A61P 35/00, C12P 21/02, G01N 33/574, C07K 16/30, C07H 21/00
US Classification:
4241391, 5303879, 5303873, 5303913, 5303917, 536 2353, 435 696, 4241781, 435 71
Abstract:
The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-I in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
Anti-Cancer Vaccines
US Patent:
2011009, Apr 28, 2011
Filed:
Feb 13, 2009
Appl. No.:
12/867083
Inventors:
Jeffrey Molldrem - Houston TX, US
International Classification:
A61K 39/00, A61K 35/12
US Classification:
424 9371, 4242771
Abstract:
The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as immunogenic compositions for treating and/or preventing breast cancer in an individual. In specific aspects, PR1 peptide or a derivative thereof, or a myeloperoxidase peptide, or a cyclin E1 or E2 peptide is provided in methods and compositions for breast cancer treatment and/or prevention. Such peptides can be used to elicit specific CTLs that preferentially attack breast cancer based on overexpression of the target protein cells.
Vaccines For Autoimmune And Infectious Disease
US Patent:
2006004, Mar 2, 2006
Filed:
Aug 26, 2004
Appl. No.:
10/927435
Inventors:
Jeffrey Molldrem - Houston TX, US
International Classification:
A61K 39/00
US Classification:
424185100
Abstract:
The present invention provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, translpant rejection or vasculitis in a patient. In particular aspects, there is provided Pr3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from Pr3, which can be used to elicit PR1-specific CTLs. The present invention also provides a HLA-restricted-peptide myeloperoxidases-based methods.
Anti-Cancer Vaccines
US Patent:
2006004, Mar 2, 2006
Filed:
Aug 26, 2004
Appl. No.:
10/926852
Inventors:
Jeffrey Molldrem - Houston TX, US
A. Barrett - Silver Spring MD, US
A. Barrett - Silver Spring MD, US
International Classification:
A61K 39/00, A61K 39/395, A61K 38/16, A61K 33/40, A61K 33/24
US Classification:
424185100, 424277100, 424649000, 514034000, 514109000, 514410000, 514449000, 514008000, 514027000, 424616000, 424155100
Abstract:
The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of the target protein cells.
Anti-Cancer Vaccines
US Patent:
2006004, Mar 2, 2006
Filed:
Aug 26, 2004
Appl. No.:
10/927634
Inventors:
Jeffrey Molldrem - Houston TX, US
International Classification:
A61K 39/395, A61K 39/00
US Classification:
424178100, 424185100
Abstract:
The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, neutrophil elastase peptides other than PR1, cyclin E1 peptides, cyclin D peptides, or cyclin E2 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack tumor cells.